These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 26212223)

  • 21. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Therapies on the Horizon for Primary Biliary Cholangitis.
    Tanaka A
    Drugs; 2024 Jan; 84(1):1-15. PubMed ID: 38082142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Primary biliary cholangitis].
    Soret PA; Chazouillères O; Corpechot C
    Rev Prat; 2021 Oct; 71(8):885-891. PubMed ID: 35147347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and management of primary biliary cirrhosis.
    Ali AH; Carey EJ; Lindor KD
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1667-78. PubMed ID: 25382237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis.
    Crippa G; Cagnoni C; Castelli A; Concesi C; Girometta S; Pancotti D; Sverzellati E; Tacchini G; Pierfranceschi MG; Carrara GC
    Clin Ter; 1995 May; 146(5):367-72. PubMed ID: 7796569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O; Wendum D; Serfaty L; Montembault S; Rosmorduc O; Poupon R
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Management of Primary Biliary Cholangitis-Strategies and Evolving Trends.
    Gao L; Wang L; Woo E; He X; Yang G; Bowlus C; Leung PSC; Gershwin ME
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):175-194. PubMed ID: 31713023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
    Corpechot C; Carrat F; Bonnand AM; Poupon RE; Poupon R
    Hepatology; 2000 Dec; 32(6):1196-9. PubMed ID: 11093724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Wong LL; Hegade VS; Jones DEJ
    Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary biliary cirrhosis in the era of liver transplantation.
    Raczyńska J; Habior A; Pączek L; Foroncewicz B; Pawełas A; Mucha K
    Ann Transplant; 2014 Sep; 19():488-93. PubMed ID: 25262831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From pathogenesis to novel therapies in the treatment of primary biliary cholangitis.
    Ronca V; Carbone M; Bernuzzi F; Malinverno F; Mousa HS; Gershwin ME; Invernizzi P
    Expert Rev Clin Immunol; 2017 Dec; 13(12):1121-1131. PubMed ID: 28994348
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
    Lirussi F; Okolicsanyi L
    Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM; Kaplan MM
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
    BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary biliary cirrhosis.
    Hohenester S; Oude-Elferink RP; Beuers U
    Semin Immunopathol; 2009 Sep; 31(3):283-307. PubMed ID: 19603170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
    Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The influence of ursodeoxycholic acid on some biochemical, immunologic and histopathologic parameters in patients with primary biliary cirrhosis].
    Skulina D; Owczarek D; Ciećko-Michalska I; Szczepański W; Tetnowski J; Garlicka M; Janas-Skulina U
    Przegl Lek; 1999; 56(3):201-4. PubMed ID: 10442009
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.